Harbour BioMed is setting sail as…
Harbour BioMed is setting sail as the Solstice begins, riding [...]
The FDA has ordered MacroGenics to…
The FDA has ordered MacroGenics to halt enrollment in a [...]
A year after Abcuro raised $200…
A year after Abcuro raised $200 million to fund a [...]
After teasing a new regulatory…
After teasing a new regulatory process for personalized genetic medicines [...]
Rome-based Angelini Pharma has…
Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts [...]
A phase 3 study of Gossamer…
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary [...]
Ionis Pharmaceuticals has pulled…
Ionis Pharmaceuticals has pulled the plug on an early investigational [...]
After an FDA rejection of its…
After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven [...]
Four years after he resigned as…
Four years after he resigned as chief medical officer at [...]
As Candel Therapeutics gears up…
As Candel Therapeutics gears up for a planned U.S. approval [...]